At the forefront of diabetes research, Diamyd Medical is revolutionizing the treatment of type 1 diabetes by pioneering the world’s first and only gene-based precision medicine confirmatory trial for individuals with Type-1 Diabetes. The phase 3 clinical trial is conducted in Europe and the US, evaluating an antigen-specific approach featuring the protein GAD65, found naturally in the body's insulin-producing cells.

The study is set to conclude in 2026, and the interest in the field is significant indicating a strong willingness among U.S. healthcare practitioners to consider prescribing Diamyd at a potential price range of USD 194,00 - 240,000.

Read the full article here